DDInter1907 DDInter178
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways. The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and active psoriatic arthritis, alone or in combination with [methotrexate]. In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Ustekinumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Ustekinumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Ustekinumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetracosactide
Ustekinumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Ustekinumab {u} may lead to a major life threatening interaction when taken with {v} Sarilumab
Ustekinumab {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Ustekinumab may lead to a major life threatening interaction when taken with Sarilumab
Ustekinumab may lead to a major life threatening interaction when taken with Natalizumab